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Abstract
The objective of this paper was to study the anti-Ehrlich ascites carcinoma effect of purified toad venom extract and its mechanism. Mouse
model of Ehrlich ascites carcinoma was established with cisplatin as the control to observe the inhibitory effect of purified toad venom extract on
malignant peritoneal effusion in mice. The results showed that compared with the control group, ascites volume, number of tumour cells and
tumour cell viability decreased and ascites inhibition rate reached over 50% in each treatment group, and with the increase of the dose, incidence
of ascites showed a downward trend. The number of tumour cells in ascites and tumour cell viability in the purified toad venom high-dose group
were lower than those of the cisplatin group. Compared with the model group, survival time was prolonged in varying degrees in the purified toad
venom groups and cisplatin group. The study concluded that purified extract of toad venom has an anti-Ehrlich ascites carcinoma effect.
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Introduction
Toad is an animal belonging to the family Bufonidae, order Anura, class Amphibia of the subphylum Vertebrata. Toad venom is the dried
secretion of Bufo gargarizans Cantor or Bufo melanostictus Schneider of family Bufonidae, which is an important Chinese medicinal material. It
is sweet in nature, pungent in taste, warm and toxic, and has the effects of detoxification, refreshing mind, subsiding swelling, inducing
resuscitation, strengthening heart, etc. (Wang et al., 1950; Liu et al., 2002). Clinically, it is widely used in the treatment of periodic facial paralysis,
acute pharyngitis, chronic hepatitis B and a variety of diseases such as cancer, and can also be used for anaesthesia and painless pulpotomy of
chronic pulpitis (Pastor et al., 2002; Chen et al., 2000). This study investigated whether bufotoxin can inhibit the growth of tumour cells in mice
with Ehrlich ascites carcinoma, as well as its toxic and side effects to various internal organs within the effective therapeutic dose range.
Materials and Methods
Test Drugs
Purified extract of toad venom was self-prepared. Other materials included cisplatin injection purchased from Nanjing Pharmaceutical
Factory Co., Ltd.
Animals and cells
Kunming mice, half male and half female, weighing 18-22 g, were purchased from the Laboratory Animal Centre of China Medical
University. Mouse Ehrlich ascites carcinoma cell lines (201110230) were purchased from Peking Union Medical College.
Model preparation
Mouse Ehrlich ascites carcinoma cells were centrifuged. Supernatant was removed, and cell concentration was adjusted to 2.0×107
cells/mL. Under aseptic conditions, each mouse was intraperitoneally administered 0.5 mL of carcinoma cell suspension. Mice bearing tumours
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7-10 d after inoculation with good general state were selected, sacrificed by cervical dislocation, and fixed in the supine position. Ascites were
extracted and centrifuged after removal of the supernatant. The remaining was cleaned twice and diluted into a 1.0×106 cells/mL carcinoma cell
suspension. The above ascites was intraperitoneally administered at 0.2 mL per mouse to establish the animal model of ascites carcinoma.
Grouping and administration
Mice were randomised into 5 groups (n=20), namely the normal saline group; cisplatin group (0.5 mg/kg); purified toad venom low-,
medium-, and high-dose groups (0.2, 1.0, and 5.0 mg/kg). After the establishment of ascites carcinoma animal model, 1 ml of different drugs was
intraperitoneally injected into mice of respective groups once daily for 10 consecutive days. On the 11th day after inoculation, half of the mice in
each group were sacrificed. Ascites were extracted and measured. The total number of tumour cells was counted, and after trypan blue staining,
tumour cell viability was calculated by microscopy. Dead mice were dissected, intra-abdominal status was observed, number of peritoneal tumour
nodules was counted, and volume of peritoneal tumour nodules was measured. Mice that were not sacrificed were observed for survival time, and
life prolongation rate was calculated thus:
Life prolongation rate = (average survival days of the treatment group - average survival days of the model group) / average survival days
of the model group.
Statistical methods
The experimental data were statistically analysed using SPSS 11.0 software, and the results were expressed as x
—
±s. The significance of
mean differences between treatment groups and model group was compared using t test.
Results
Inhibitory effect of purified toad venom extract on malignant ascites in mice
Compared with the control group, ascites volume, number of tumour cells and tumour cell viability decreased and ascites inhibition rate
reached over 50% in each treatment group, and with the increase of the dose, incidence of ascites showed a downward trend. The number of
tumour cells in ascites and tumour cell viability in the purified toad venom high-dose group were lower than those of the cisplatin group. The
results are shown in Table 1.
Table. 1: Inhibitory effect of purified toad venom extract on malignant ascites formation and tumour cells in mice (x
—
±s)
Group Dose (mg/
kg)
Incidence
of ascites
(%)
Volume of
ascites (ml)
Ascites
inhibition
rate (%)
Number of tumour
cells (106/m)
Tumour cell
survival rate (%)
Control
group
100 12.30 29.38±2.57 91.24±4.59
Cisplatin
group
0.5 72 2.92* 76.3 6.75±2.49* 57.49±5.39*
0.2 84 5.81* 52.8 14.68±2.57* 78.65±5.34*
1.0 73 3.74* 69.6 8.76±2.67* 69.51±2.88*
Purified
toad
venom grou
p
5.0 62 1.12* 90.9 3.52±2.31* 48.59±4.12*
Note: Comparison with the control group, * P<0.05, the same below.
Effect of purified toad venom extract on survival time of mice
Mice in the model group died generally about 15 d after intraperitoneal inoculation of EAC cells, indicating that the experimental
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conditions were stable, which were in line with the evaluation criteria. Compared with the model group, survival time was prolonged in varying
degrees in the purified toad venom groups and cisplatin group, of which the prolongation of survival time was most apparent in the purified toad
venom high-dose group, showing a significant difference. Average survival time and life prolongation rate of mice are shown in Tab. 2.
Tab. 2: Effect of purified toad venom extract on survival time of mice (x
—
±s, n=10)
Group Dose (mg/kg) Survival time / d Life prolongation
rate (%)
Model group 15.39±2.79 --
Cisplatin group 0.5 18.12±3.51* 17.77
0.2 20.34±4.27* 32.16
1.0 21.79±4.65* 41.59
Purified toad
venom group
5.0 24.20±3.49* 57.24
Side effects of purified toad venom extract in mice
5 mice showed vomiting, and 2 mice presented mild weight loss in the cisplatin group. In the high-dose purified toad venom group, 3 mice
showed vomiting, and 8 mice presented obvious emaciation and weight loss after 5 times of medication. No obvious toxic and side effects were
noted in other groups.
Discussion
Toad venom has a complex chemical composition, which mainly includes bufadienolides, cardenolide bufotoxins, indole alkaloids, sterols,
as well as adrenaline, proteins and polysaccharides. Toad venom is extremely widely applied in clinical settings, especially in recent years. The
anti-tumour effect of toad venom has attracted great attention of scholars from home and abroad (Fan et al., 2006; Hu et al., 2008). In 1969,
Sondheimer et al. synthesized bufogenin — bufalin and resibufogenin, which marked the beginning of molecular level research of toad toxins,
laying a solid foundation for further revelation of anti-tumour mechanism of bufotoxins, clinical novel drug research and development, as well as
batch launch of bufalin and other related products.
The pathogenesis of malignant ascites is very complex, and it mainly includes injury of peritoneal serosa by tumour causing increased
capillary permeability, making more protein leakage into the serous cavity; it also includes poor return of blood vessels and lymph vessels due to
tumour compression, or the embolization of tumour cells can also lead to ascites, and severe hypoproteinemia can also inhibit the reabsorption
process.
Clinical and animal experiments in recent years have found that VEGF can stimulate division and proliferation of tumour vascular
endothelial cells and increase vascular permeability, and can play an important role in the formation of ascites. VEGF level is high in more benign
ascites, which is of value in the diagnosis of malignant ascites (Mori et al., 2000; Sun et al., 2004a; Sun et al., 2004b; Zhao et al., 2004) We
applied purified extract of toad venom to treat the animal model of mouse ascites carcinoma, and got good results, providing an experimental
basis for the clinical application of angiogenesis inhibitors in the treatment of malignant ascites.
Our experimental results showed that the purified extract of toad venom could significantly inhibit the growth of Ehrlich ascites carcinoma
cells in vivo in tumour-bearing mice and prolong their survival time within the concentration range of 0.5-5.0 mg/kg, which were positively
correlated to the dose. The prolongation of survival time of experimental mice was most apparent in the purified toad venom extract high-dose
group, which was of significant difference.
Cinobufagin is a water-soluble bufotoxin extracted from toad skin. Researchers often use cinobufagin as a positive control to explore the
anti-tumour activity of toad venom in mice in vivo. Our experiment demonstrated that cinobufagin can significantly inhibit the growth of Ehrlich
ascites carcinoma cells in vivo in mice and prolong their survival time. But with the increase in the amount of cinobufagin, large dose can cause
oedema, degeneration and focal necrosis of myocardial cells, which can limit the clinical application of cinobufagin. This experiment confirmed
that the effective dose for anti-Ehrlich ascites carcinoma of further isolated and purified product of toad venom is much lower than cinobufagin,
suggesting that the high purity toad venom extract will further broaden the range of clinical medication of toad venom.
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